D-0543-2024 Class III Ongoing
FDA drug recall D-0543-2024 was initiated by Zydus Pharmaceuticals (USA) Inc on May 16, 2024 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications. The recall status is ongoing. Affected quantity: 13,440 units.
Recall details
- Product Type
- Drugs
- Report Date
- Jun 12, 2024
- Initiation Date
- May 16, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 13,440 units
Product description
Estradiol Transdermal System, USP (Twice-Weekly) 0.025mg/day, Rx Only, Manufactured by: Cadila Healthcare Limited, Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1191-8
Reason for recall
Failed Impurities/Degradation Specifications.
Distribution pattern
Nationwide within the United States
Code information
Lot #: M311202, Exp. Date 2/25; M311201, Exp. Date 1/25
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0543-2024
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026